This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mehta J, Kelsey S, Chu P et al. Amphotericin B complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies Bone Marrow Transplant 1997 20: 39–43
Wingard JR . Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses Bone Marrow Transplant 1997 19: 343–347
Cook G, Franklin IM . Adverse drug reactions associated with the administration of amphotericin B lipid complex (Abelcet) Bone Marrow Transplant 1999 23: 1325–1326
Wingard JR, White MH, Anaissie EJ et al . A randomized double-blind comparative safety trial of AmBisome and Abelcet in febrile neutropenic patients. Focus on fungal infections, 17–19 March 1999, Abstr. 015
Ringdén O, Andström E, Remberger M et al. Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin Bone Marrow Transplant 1994 14: (Suppl. 5) S10–S14
Ringdén O, Andström E, Remberger M et al. Allergic reactions and other rare side-effects of liposomal amphotericin Lancet 1994 344: 1156–1157
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ringdén, O., Tollemar, J. Response to Dr Furebring. Bone Marrow Transplant 25, 342–343 (2000). https://doi.org/10.1038/sj.bmt.1702157
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1702157